Regis Healthcare (ASX:REG) Backed by Buy and Outperform Ratings from Three Brokers

Sonal Goyal

24 September 2025 12:10 PM AEST

Regis Healthcare (ASX:REG) Backed by Buy and Outperform Ratings from Three Brokers

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Three brokers have assigned Buy, Outperform or Overweight ratings on Regis Healthcare.

Target prices range between AUD 7.90 and AUD 8.50, representing an upside of 20%–30% from the current share price.

Regis Healthcare shares traded at AUD 6.45, down 1.23% during trading session on 24 September 2025.

Regis Healthcare Limited (ASX:REG) has received supportive coverage from three brokers, each assigning a positive rating with price targets indicating meaningful upside from current market levels. The company, one of Australia’s leading residential aged care providers, continues to improve its operational and financial profile, with brokers reaffirming confidence in its outlook.

Analyst Ratings

The three brokers covering Regis Healthcare have issued favourable recommendations. Price targets have been set at AUD 7.90, AUD 8.20, and AUD 8.50, compared with the latest market price of AUD 6.45. These targets suggest potential upside ranging from 20.98% to 30.17%.

The average target across the three ratings equates to AUD 8.20, reflecting an implied upside of 27.1%.

Share Price Performance

On 23 September 2025, Regis Healthcare’s shares closed at AUD 6.45, down AUD 0.08 or 1.23% from the previous session. Trading volumes stood at 284,718 shares. Despite near-term market volatility, broker valuations suggest the company remains attractively positioned for investors.

Company Update

Regis Healthcare recently provided an update on government funding reforms for the aged care sector. The company noted that while changes to the Australian National Aged Care Classification (AN-ACC) model are expected to result in a 2.6% funding increase from 1 October 2025, this remains below anticipated levels.

Additionally, the group has completed the acquisition of four Rockpool residential aged care homes, adding 600 beds to its portfolio and supporting growth momentum. Occupancy remains favourable, with mature home levels at 96.5% as of 18 September 2025.

Financial Performance

For FY25, Regis reported revenue of AUD 1.16 billion, up 15% on the prior year. Underlying EBITDA rose 17% to AUD 125.8 million, while underlying NPAT grew 37% to AUD 53.4 million. Statutory NPAT was AUD 49.0 million, representing a 329% increase.

The company generated net operating cash flow of AUD 306.1 million, including AUD 195.4 million in refundable accommodation deposits (RADs) net inflows. The Board declared a final dividend of 8.13 cents per share, bringing total FY25 dividends to 16.22 cents, equivalent to 100% of NPAT.

Outlook

Looking ahead, Regis expects FY26 underlying EBITDA in the range of AUD 130 million to AUD 135 million, reflecting growth of 3% to 7% on FY25. The company has set a target to expand to 10,000 available beds by FY28, up from approximately 7,600 as of June 2025.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.